14102 studies
BACKGROUND: Multiple Sclerosis (MS) is a chronic autoimmune neurodegenerative condition causing demyelination and axonal damage. Ethidium bromide (EBrD) induces focal demyelination by damaging glial cells, especially oligodendrocytes and astrocytes.…
BACKGROUND: Cardiovascular disease (CVD) disproportionately affects type 2 diabetes (T2D) patients with chronic kidney disease (CKD). Although semaglutide shows cardiometabolic benefits, its efficacy across CVD endpoints and high-risk CKD subgroups r…
INTRODUCTION: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retinopathy (DR) complications including proliferative DR (PDR) and…
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering…
IMPORTANCE: Metabolic dysfunction-associated steatohepatitis (MASH) represents a high, underprioritized burden among noncommunicable diseases (NCDs) and people living with type 2 diabetes (T2D). OBJECTIVE: To identify cost-effective management approa…
BACKGROUND: Off-label use of semaglutide as Ozempicfor weight loss has surged in the Arab populations in the absence of structured real-world evaluation. OBJECTIVE: To assess utilization patterns, effectiveness, and patient satisfaction with off-labe…
Causal mediation analysis is an important tool in medical research, enabling researchers to examine and quantify the mechanisms through which a treatment exerts its effects on an outcome of interest. In many studies, the potential mediator is measure…
This practice recommendation serves as an update to the 2023 AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD),…
BACKGROUND: Type 2 diabetes (T2D), affecting approximately 12% of the global population and over 30% of older adults, is among the most prevalent and fast-growing risk factors for neurodegenerative disorders. Evidence is lacking on whether specific g…
PURPOSE OF REVIEW: This review aims to evaluate the effectiveness of GLP-1 receptor agonists, and metabolic and bariatric surgery in managing childhood obesity and associated conditions. It discusses current trends, challenges, and the potential of t…
Postprandially reabsorbed bile acids, along with various peptide hormones released following a meal, orchestrate complex events associated with digestion and prepare the body for the disposal of incoming nutrients by regulating metabolism. Interestin…
INTRODUCTION: Given the global increase in obesity prevalence, there has been an emergence of a multitude of treatment options, specifically less invasive operations, like intragastric balloons, and pharmaceutical treatments like semaglutide. The aim…
INTRODUCTION: Although the association between semaglutide use for diabetes or obesity and non-arteritic ischemic optic neuropathy (NAION) has been investigated, the relative risk has not been established in large, racially diverse populations. Given…
Study DesignRetrospective Cohort StudyObjectiveThis study investigated the association between perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy and pseudoarthrosis rates in patients undergoing long-segment spinal deformity su…
To evaluate the efficacy and safety of orlistat, glucagon-like peptide-1 receptor agonists (GLP-1RA), and the combination of phentermine and topiramate in the treatment of childhood obesity.Relevant literature on anti-obesity drug treatments for chil…
OBJECTIVES: We hypothesized that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and treatment currently U.S. Food and Drug Administration (FDA) approved to reduce worsening of kidney disease and kidney failure may protect against…
Familial partial lipodystrophy (FPLD) is a rare genetic disorder leading to adipose tissue deficiency/redistribution and metabolic dysregulation with insulin resistance, diabetes mellitus, and dyslipidemia. Coincidence of FPLD and autoantibody-positi…